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Summary
 
Objective and design
 
 
 
Depot somatostatin analogues are well
accepted as either adjuvant or primary therapy for acromegaly, and
their long dosage intervals facilitate adherence to treatment. Our
objective was to evaluate whether lanreotide Autogel® 120 mg, every
4–8 weeks, was as effective in controlling acromegaly as lanreotide
microparticles 30 mg, every 1–2 weeks.
 
Patients design and measurements 
 
Patients who had used lanreotide
microparticles 30 mg, 
 
≥
 
 2 months prestudy, and had responded to
treatment were recruited to this open, prospective, multicentre phase
III trial. Three to ﬁve injections of lanreotide Autogel® 120 mg were
administered. Lanreotide Autogel® 120 mg was injected every 4, 6
or 8 weeks in patients previously receiving lanreotide microparticles
every 7, 10 or 14 days, respectively. GH and insulin-like growth factor
(IGF)-1 levels were assessed one dosing interval after the ﬁnal injections.
 
Results 
 
Ninety-eight patients were enrolled and 93 completed.
Steady-state GH concentrations demonstrated similar efﬁcacy between
the formulations (upper 95% conﬁdence interval of the quotient,
77·7%). Mean (SE) GH levels were lower with lanreotide Autogel®
than with lanreotide microparticles (3·8 (0·5) 
 
vs
 
 4·3 (0·5) ng/ml;
 
P
 
 < 0·001). GH levels < 2·5 ng/ml were observed in 54% and 46%
of patients; 40% and 35% having GH < 2·5 ng/ml and normalized
IGF-1 with lanreotide Autogel® and microparticles, respectively.
Symptoms were controlled better with lanreotide Autogel® and
treatment was well accepted.
 
Conclusions 
 
Lanreotide Autogel® 120 mg every 4–8 weeks, is at
least as effective and as well tolerated in acromegaly as lanreotide
microparticles 30 mg injected every 7–14 days.
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Introduction
 
The efﬁcacy of somatostatin analogues in the treatment of acromegaly
is determined by the number, distribution and activity of somatostatin
receptors in the pituitary GH-producing adenoma.
 
1,2
 
 Somatostatin
analogues are indicated principally for the treatment of acromegaly
that remains active after transsphenoidal surgery, whether or not
the patient has also undergone radiotherapy. Somatostatin ana-
logues have, however, also been used in selected patients as primary
treatment, for example in those whose vision is not compromised
by the presence of the tumour or whose tumours are unlikely to be
excised completely (e.g. macroadenomas, invasive adenomas).
 
3,4
 
These analogues can also be beneﬁcial prior to surgery, and tumour
size is reduced in 30% of patients given lanreotide for 1–3 months
before transsphenoidal surgery.
 
5
 
Long-term use of somatostatin analogues has been made easier
by the development of prolonged-release formulations.
 
6
 
 Octreotide
is available as a 4-week formulation (octreotide LAR)
 
7
 
 and lanreotide
as either a 1–2 week microparticle (MP) formulation or a 4-week
aqueous Autogel® (ATG) formulation.
 
8–11
 
 When given by deep
subcutaneous (sc) injection every 4 weeks at 60, 90 or 120 mg, the
Lan ATG formulation is as effective at controlling levels of GH and
IGF-1 as either the Lan MP 30  mg formulation
 
8,12
 
 or octreotide
LAR.
 
13–15
 
By maintaining the same total monthly dose, but with fewer injections,
the prolonged-release formulations offer clear treatment advantages.
The aim of our study (study A92 52030 046) was to evaluate whether
the dosing interval of Lan ATG could be extended beyond 4 weeks,
without compromising efﬁcacy or safety. Thus, we investigated
whether Lan ATG 120 mg administered at intervals of 4, 6 or 8 weeks,
had no less efﬁcacy than Lan MP 30  mg administered every 7–
14 days. We also compared the safety of the two formulations.
 
Patients and methods
 
Patients
 
Patients who were eligible for this study had a diagnosis of acromegaly,
deﬁned as GH levels over 2 ng/ml after an oral glucose tolerance test,
and IGF-1 concentrations elevated above the age- and sex-matched
normal range. Patients whose last radiotherapy was over 10 years
previously were required to have had active acromegaly conﬁrmed
in the 12 months before inclusion in the study. In cases of incomplete
tumour excision, as evidenced by imaging, one blood sample showing
GH levels over 5 ng/ml qualiﬁed as acromegaly. Eligible patients had
responded to somatostatin analogues, deﬁned as a reduction in GH
of 50% or more from baseline, normalization of IGF-1 or a reduction
of 30% or more, after a minimum period of 2 months of treatment.
All patients had used Lan MP 30 mg at ﬁxed intervals of adminis-
tration, for a minimum of 2 months immediately before their inclu-
sion. Patients were excluded if they had received treatment with
octreotide LAR in the last 5  months; received treatment with
dopaminergic agonists in the 2 months before the study; or under-
went radiotherapy for acromegaly within 2 years prior to starting the
study. All patients gave written informed consent, and the study was
approved by the Ethics Committee of each participating centre and
by the Health Authorities of the participating countries. The study
was carried out in accordance with the guidelines of the Declaration
of Helsinki.
 
Study design
 
This study was a phase III, open, multicentre, prospective study, in
which patients served as their own controls as they switched between
treatments. Patients were injected with Lan ATG 120 mg at a
frequency determined by their dosage interval with Lan MP 30 mg
at the time of their inclusion. This interval had been chosen by the
investigators in order to optimally control their disease. The total
monthly dose of Lan was, therefore, kept constant as patients switched
between formulations. Lan ATG 120 mg was injected every 8 weeks
when the dosing interval with Lan MP 30 mg was every 14 days, and
every 6 or 4 weeks for Lan MP administered every 10 and 7 days,
respectively. There was no washout period. Three injections of Lan
ATG were planned for each treatment group, but some patients,
whose vacation period interfered with the trial completion, received
ﬁve injections. There was no dose titration. The duration of
treatment with Lan ATG ranged from 84 to 210 days. Lan MP 30 mg
was given by intramuscular injection, whereas Lan ATG 120 mg was
given by deep sc injection.
 
Efficacy and safety assessments
 
Blood samples were taken immediately before the ﬁnal injection of
Lan MP, before the ﬁnal injection of Lan ATG and at times after the
ﬁnal injection of Lan ATG, according to the dosing interval. For
patients with 8-week dosing, samples were taken at weeks 1, 2, 5 and
8 after the ﬁnal Lan ATG injection; for 6-week dosing, samples were
taken at weeks 1, 2, 4 and 6, and for 4-week dosing, samples were
taken 1, 2, 3 and 4 weeks after the last Lan ATG injection. At each
sampling time, blood was taken every 30 min over a 4-h period. All
samples were used to determine GH concentrations, whereas only
the ﬁrst samples from each series were used for IGF-1 and Lan
assessment.
Symptoms of acromegaly were assessed at the beginning and at
the end of the study. Symptoms such as headache, hyperhidrosis,
asthenia and arthralgia were graded as: none, mild (present but does
not interfere with normal daily activity), moderate (normal daily
activity difﬁcult) or severe (impedes normal daily activity). Patients
also expressed their satisfaction with the treatment at the end of the
study using a visual analogue scale ranging from 1 to 10, with the
score of 10 as maximum acceptance of treatment.
Both systemic and local tolerability were recorded after each
administration. Systemic tolerability included the incidence and
severity of nausea, diarrhoea, abdominal distension, abdominal pain
and cramps. Tolerability at the injection site was monitored 30 min
after each injection at which investigators noted the presence of heat,
erythema or local indurations. Patients evaluated any pain relating
to the administration of the drug using a visual analogue scale
ranging from 0, absence of pain to 10, maximum pain imaginable.
All adverse events reported were recorded. Biliary ultrasounds were
performed and standard haematological and biochemical tests were
undertaken at the beginning and at the end of the study. 
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Analytical determinations
 
All analytical assays were processed centrally. GH concentrations
were  measured with an immunoradiometric assay from Nichols
Institute Diagnostics (San Juan de Capistrano, CA), with a detection
limit of 0·02 ng/ml and intra- and interanalysis variation coefﬁcients
of 5·1% and 14·9%, respectively. IGF-1 was measured with an
immunoradiometric assay, also from Nichols Institute Diagnostics,
with a detection limit of 4·6 ng/ml and intra- and interanalysis
variation coefﬁcients of 5·9% and 5·9%, respectively. Serum levels
of Lan were determined using an immunoradiometric method
validated previously, with a detection limit of 0·078 ng/ml and
coefﬁcients of variation between 2·3% and 13·6%.
 
16
 
Statistical evaluation
 
We tested the hypothesis that the new prolonged-release formulation
Lan ATG 120 mg administered every 4, 6 or 8 weeks is no less
effective than Lan MP 30 mg administered every 7–14 days in the
control of acromegaly. To determine similar efﬁcacy, steady-state GH
concentrations with Lan ATG and Lan MP were determined, and the
quotient of the GH concentrations calculated. Noninferiority would
be demonstrated if the 95% conﬁdence interval (CI) of this ratio had
an upper limit below 125%, assuming log transformation of the data.
Differences between matched values were evaluated using the paired
 
t
 
-test or the Wilcoxon-signed rank test, depending on the necessity
of a parametric test. The McNemar test was used for dichotomy
variables.
Using the criteria established for bioequivalence studies,
 
17
 
 a
sensitivity of 20% and a coefﬁcient of variation of 80·48%, we
calculated that a sample of 102 patients would be necessary to
guarantee a study power of 80%. Only 98 patients were enrolled,
however, as a preliminary analysis with 74 patients showed that
statistical signiﬁcance had already been obtained. Both the per-
protocol (PP) population and those patients who had completed the
study were included in the analyses.
 
Results
 
Patients
 
A total of 98 patients with acromegaly were enrolled in centres across
Spain and Portugal. One patient withdrew consent before receiving
any medication; the remaining 97 patients who received at least one
injection of Lan ATG 120  mg constituted the safety population.
Demographic characteristics for the safety population are shown in
Table 1. Three of the safety population did not complete the study
and one patient had no valid hormonal determinations after treat-
ment; thus, there were 93 patients in the completers group. Eighty
patients completed the study without protocol deviations and
formed the PP population.
All patients comprising the safety population had been diagnosed
with acromegaly a mean (
 
±
 
 SE) of 9·4 
 
±
 
 0·7 years before inclusion in
the study. Previous treatment for acromegaly included adenomectomy
in 76/97 (78%) patients, whereas 53/97 (55%) had received pituitary
radiotherapy for a minimum of 2 years before inclusion. The
mean (
 
±
 
 SE) duration of somatostatin analogue treatment prior to
study inclusion was 3·1 
 
±
 
 0·3 years. Lan ATG 120 mg was injected
every 4, 6 or 8 weeks for 13 (13%), 31 (32%) and 53 (55%) patients,
respectively.
 
Hormonal control and drug levels
 
Similar efﬁcacy between the different formulations was shown by the
upper limit of the 95% CI for the mean ratio of GH concentrations,
with Lan ATG 120 mg over Lan MP 30 mg being less than 125%. This
was true for both the completers (upper 95% CI, 77·7%) and the
PP population (upper 95% CI, 76·8%). Also, similar efﬁcacy between
Lan ATG 120 mg and Lan MP 30 mg was shown separately for each
of the 4-, 6- and 8-week dosing groups for each time-point analysed
(Fig. 1). A check for homogeneity between three and ﬁve injections
was performed.
Mean GH concentrations after treatment with Lan MP 30 mg, and
at times after the ﬁnal dose of Lan ATG 120 mg are shown in Table 2.
For both the PP population (
 
P <
 
 0·001) and the completers group
(
 
P <
 
 0·001), mean GH levels were lower one dosing interval after the
ﬁnal injection of Lan ATG 120 mg than one dosing interval after
treatment with Lan MP 30 mg. Control of GH levels below 2·5 ng/ml
was achieved in 46% of patients with Lan MP 30 mg and in 54%
of patients with Lan ATG 120  mg (
 
P =
 
  0·052). Whereas 35% of
patients had both GH levels below 2·5 ng/ml and IGF-1 normalized
in accordance with age and sex with Lan MP 30 mg this level of
control was present in 40% of patients after treatment with Lan ATG
120 mg. Plasma concentrations of IGF-1 did not change signiﬁcantly
over the course of the study. During treatment with Lan MP 30 mg,
the mean plasma concentration of IGF-1 was 423 
 
±
 
 30 ng/ml in men
and 336 
 
±
 
 24 ng/ml in women, compared with 414 
 
±
 
 32 in men and
314 
 
±
 
 23 ng/ml in women after treatment with Lan ATG 120 mg. The
percentage of patients with IGF-1 within the normal range for age
and sex remained unchanged between baseline (55%) and at the end
of the study (56%).
Table 3 summarizes the plasma concentrations of Lan according
to dosage intervals. There was no difference in minimum concen-
trations of Lan between the Lan MP and the Lan ATG formulations
when dosing was equivalent. Similarly, Lan concentrations did not
differ at 4 and 6 weeks, irrespective of whether three or ﬁve injections
had been administered (Table 3). All patients on 8-week dosing had
received three doses.
Table 1. Demographic and baseline characteristics of patients (safety 
population, n = 97)
Male/female, n 44/53
Age, years 50·6 (13·6)
Body mass index, kg/m
2 30·1 (5·1)
Cholelithiasis, n (%) 25/90 (27·8)
High blood pressure, n (%) 36/97 (37·1)
Diabetes mellitus, n (%) 23/97 (23·7)
Systolic blood pressure, mmHg 134·1 (19·6)
Diastolic blood pressure, mmHg 82·7 (12·2) 
Data are presented as mean (SD) unless stated otherwise. 
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Symptom control
 
The symptoms of acromegaly were generally of mild or moderate
intensity. Overall, greater symptom control was noted at the end of
treatment with Lan ATG 120 mg than with Lan MP 30 mg (Fig. 2).
The improvement was statistically signiﬁcant with regard to
hyperhidrosis (
 
P <
 
 0·001) and headache (
 
P <
 
 0·001).
 
Acceptance of treatment
 
Lan ATG 120 mg was well accepted by patients, with a mean accept-
ance score of 8·3 (95% CI, 7·9–8·7), from a maximum possible score
of 10. Results were similar between dosing groups, with a mean (95%
CI) of 8·2 (7·0–9·3), 8·4 (7·5–9·2) and 8·3 (7·9–8·8), for adminis-
tration every 4, 6 and 8 weeks, respectively.
Fig. 1 Mean ratio of GH levels and upper limit of 
conﬁdence interval (95%) for the mean GH ratio at 
different times (weeks after the last Lan ATG 
injection) throughout the last dosage interval 
(log-transformed values).
Table 2. Concentrations of GH after the last dose of Lan MP, 30 mg and at times after the last dose of Lan ATG, 120 mg
GH (ng/ml) 
Per protocol population (n = 80) Completers (n = 93)
Lan MP, 30 mg
One dosing interval after ﬁnal injection 4·1 (0·5) 4·3 (± 0·5)
Lan ATG, 120 mg
Immediately before ﬁnal injection 3·6 (± 0·6)*** 3·8 (± 0·5)***
+1 week after ﬁnal injection 2·5 (± 0·3)*** 2·5 (± 0·3)***
+2 weeks after ﬁnal injection 2·2 (± 0·3)*** 2·5 (± 0·4)***
+3–5 weeks† after ﬁnal injection 2·9 (± 0·4)*** 3·0 (± 0·4)***
+1 dosing interval‡ after ﬁnal injection (end of study) 3·7 (± 0·5)** 3·8 (± 0·5)***
Data are presented as mean (± SEM). **P < 0·001; ***P ≤ 0·0001 vs baseline visit.
†3, 4 or 5 weeks from last dose for 4-, 6- or 8-week dosing, respectively.
‡4, 6 or 8 weeks from the last dose for 4-, 6- or 8-week dosing.
Dosing interval
Minimum serum Lan (ng/ml) 
Lan MP, 30 mg Lan ATG, 120 mg
Lan MP 7 days/Lan ATG 4 weeks
Three doses of Lan ATG (n = 8) 2·6 (0·4) 2·4 (0·3)
Five doses of Lan ATG (n = 5) 2·1 (0·4) 2·4 (0·3)
Lan MP 10 days/Lan ATG 6 weeks
Three doses of Lan ATG (n = 11) 1·8 (0·2) 1·9 (0·2)
Five doses of Lan ATG (n = 16) 2·0 (0·2) 2·2 (0·2)
Lan MP 14 days/Lan ATG 8 weeks
Three doses of Lan ATG (n = 53) 1·4 (0·1) 1·6 (0·1)
Data are presented as mean (SEM). Samples were taken one dosing interval after the last dose of study.
Table 3. Minimum serum concentration of Lan by 
dosing interval of Lan MP and Lan ATG, and by 
number of doses of Lan ATG (completers, n = 93) 
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Adverse events
 
There were no serious adverse events related to either Lan ATG
120 mg or Lan MP 30 mg. One patient died while participating in
the study, but this was not considered related to the study drug. The
patient had been diagnosed with acromegaly 9 years before inclusion
in the study and had been receiving regular treatment with Lan MP
for 2 years and 4 months without any tolerability problems. He did,
however, have a history of dilated cardiopathy and auricular ﬁbril-
lation. The patient was admitted for coughing and dyspnoea and,
while in the hospital, suffered general deterioration and various
cardiovascular complications. He died from cardiovascular shock
and intravascular coagulation. One patient withdrew because of the
persistency of acromegaly symptoms and one patient withdrew
because of pain radiating from the left leg after the ﬁrst dose of Lan
ATG.
The most common adverse events were gastrointestinal in nature;
51% of patients reported diarrhoea, 42% ﬂatulence, 41% abdominal
pain and 14% nausea at some time during their treatment with Lan
ATG. Systemic and local tolerability for the last doses of Lan MP and
Lan ATG are shown in Table 4. Gallbladder ultrasound was
performed in 90 patients at the beginning of the study and in 84
patients at the last visit. Overall, the prevalence of lithiasis or sludge
did not alter over the study (34/90 at selection visit and 32/84 at last
visit); whereas six patients developed lithiasis or sludge during the
study, these abnormalities were present initially and disappeared
during the study period in seven patients. No signiﬁcant alterations
were detected in any of the clinical or analytical parameters evaluated.
 
Discussion
 
This study compares the efﬁcacy between Lan ATG 120 mg admin-
istered at intervals of 4, 6 or 8 weeks and Lan MP 30 mg administered
every 7–14 days in patients with acromegaly who were responsive to
treatment with somatostatin analogues.
The longer dosing period with Lan ATG was at least as efﬁcacious
in controlling levels of GH as 7–14-day dosing with Lan MP. Similar
efﬁcacy was demonstrated by the upper limit of the 95% CI, for the
quotient of GH concentrations under Lan ATG and Lan MP falling
below 125%. This was also shown for each of the different dosing
intervals with Lan ATG and Lan MP, and at each time-point assessed.
Furthermore, a trend towards superior control of GH was observed
with lan ATG, as levels of GH were signiﬁcantly lower than in those
treated with Lan MP and control of GH, deﬁned as plasma concen-
trations below 2·5 ng/ml, was better with Lan ATG. Whereas only
46% of patients had GH control with Lan MP this increased to 54%
in those treated with Lan ATG, although this just missed statistical
signiﬁcance. The therapeutic objective of GH control below 2·5 ng/ml
and concentrations of IGF-1 within the normal range is widely
used, as patients with acromegaly who have this level of control have
a mortality rate similar to that of the general population.
 
18–23
 
 This
also showed a trend to superiority on lan ATG, with 40% patients
showing good biochemical control, rising from 35% on Lan MP.
The proportion of patients with GH and IGF-1 control in the
present study is similar to results from previous studies with Lan
 
8,24,25
and octreotide.
26 Notably, control was achieved in this study even
though over half of the patients had an injection frequency of every
8 weeks. These comparisons indicate that patients who are well
controlled on Lan ATG can use an extended dosing interval without
compromising efﬁcacy. The longer dosing interval is also likely to
provide cost savings through fewer injections needing to be given.
As seen in previous studies with Lan and octreotide, a proportion
of all patients were poorly responsive, despite receiving high doses
of somatostatin analogue. Thus, patients receiving Lan MP every
7 days/Lan ATG every 4 weeks had higher mean GH concentrations
than patients with less frequent injections. Poorly responsive patients
are likely to have a GH-secreting adenoma with a somatostatin recep-
tor proﬁle that is not preferential to Lan or octreotide, which bind
to type 2 and 5 receptors.
27,28 These patients could be candidates for
supplementing somatostatin analogue treatment with weekly doses
of the GH antagonist, pegvisomant or with a dopaminergic agonist.
Both approaches can signiﬁcantly improve biochemical control of
acromegaly.
29,30
Fig. 2 Presence and intensity of the symptoms of acromegaly after treatment 
with lanreotide microparticles (Lan MP), 30 mg, or Lan ATG, 120 mg. 
The percentage of patients reporting symptoms at the selection visit was 
compared with the percentage of patients having symptoms at the ﬁnal visit 
through a McNemar’s test.
Table 4. Percentage of patients with digestive adverse events or adverse 
events at the injection site: comparison after ﬁnal injections of Lan MP, 
30 mg, or Lan ATG (safety population, n = 97)
Lan MP, 30 mg Lan ATG, 120 mg
Digestive tolerability, %
Abdominal distension 36 29
Diarrhoea 34 27
Abdominal pain 24 20
Abdominal cramps 13 5
Nausea 11 8
Local tolerability, %
Induration 19 17
Erythema 4 0
Heat 9 6
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Patients recruited to this study had used previous medical, surgical
and radiological therapies to control their acromegaly. Among the
study population, 78% had undergone adenomectomy and 55%
radiotherapy. To minimize any bias from the effects of radiotherapy,
patients were excluded if they had completed their treatment in the
preceding 2 years. Thus, this exclusion avoided the period in which radio-
therapy exerts its maximum effect. For patients who had completed
radiotherapy in the previous 10 years, the activity of the disease was
documented during the year prior to their inclusion in the study.
The symptoms of acromegaly were less severe during treatment
with Lan ATG 120 mg than with Lan MP 30 mg with a signiﬁcant
improvement in headache and hyperhidrosis. Patients showed a high
level of acceptance of treatment with Lan ATG 120 mg with a mean
score of 8·3 (95% CI, 7·5–9·2) out of a maximum of 10. Acceptance
of Lan MP was not assessed.
Side effects were mostly gastrointestinal in nature and of mild to
moderate intensity, as reported in previous studies with somatostatin
analogues.
8,13,25,31 Lan ATG showed a trend towards an improved
digestive tolerability compared with Lan MP. This has been reported
previously and may relate to the pharmacokinetic characteristics of
Lan ATG; whereas Lan has a smooth release proﬁle from ATG with
a minimal initial burst effect, it is released rapidly from the surface
of the MP copolymers, resulting in a peak in the plasma concentration
of drug.
8,9,32 A second factor that may contribute to improved
tolerance with Lan ATG is that in the clinical experience of the study
investigators, the incidence of gastrointestinal symptoms is usually
limited to the ﬁrst days following administration of a somatostatin
analogue. Extension of the dosage interval, with a concomitant
reduction in the number of administrations, may therefore provide
an overall reduction in the number of digestive events.
In conclusion, treatment with Lan ATG administered every 4–
8 weeks was at least as effective and well tolerated as Lan MP admin-
istered every 7–14 days in patients with active acromegaly. There was
a good level of acceptance of Lan ATG. The longer dosing interval
of Lan ATG 120 mg therefore maintains the same overall monthly
dose as Lan MP 30 mg but with four times fewer injections, and thus
has a beneﬁt in terms of cost and patient compliance.
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